A clinical study to find whether dexmedetomidine provides adequate comfort to patients during awake nasal fibreoptic intubatio
Phase 4
Completed
- Conditions
- Health Condition 1: null- Scheduled for awake nasal fibreoptic intubation in view of assessed difficult airway
- Registration Number
- CTRI/2012/09/002948
- Lead Sponsor
- Kasturba Hospital KMC Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
All patients between 18-85 years undergoing awake nasal fibreoptic intubation
Exclusion Criteria
•ASA physical status IV
•Raised intracranial pressure
•Uncontrolled seizure disorder and/or known psychiatric illness
•Current (in the past 14 days) treatment with an α2 agonist or antagonist
•Patients in whom dexmedetomidine or benzodiazepine administration is contra-indicated
•Patients with acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate < 50 bpm, systolic blood pressure (SBP) < 90 mmHg, or complete heart block unless they have a pacemaker
•Patients with elevated SGPT (ALT) and/or SGOT (AST) values of > 2 times the upper limit of normal.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety and effectiveness of dexmedetomidine for sedation during awake nasal fiberoptic intubationTimepoint: Endoscopy time, intubation time and intubation score were done during and immediately following awake fibreoptic intubation
- Secondary Outcome Measures
Name Time Method adverse eventsTimepoint: during intubation and 24 h after surgery